Ability of Rare Sugar Members to Release Glucagon-Like Peptide-1 and Suppress Food Intake in Mice

Why GLP-1 matters for functional foods

You know GLP-1 for diabetes and weight loss drugs. Now think of it as a food industry target. A new study in Nutrients (DOI: 10.3390/nu17071221) put D-allulose to the test in mice. The result? It raised active GLP-1 and cut short-term food intake. The effect depended on GLP-1 receptor signaling. If you develop satiety products, this matters.

Rare sugars: more than low-calorie sweeteners

Rare sugars occur naturally in small amounts. They taste sweet but deliver few calories. That combination already makes them attractive to food formulators. D-allulose sits in this group. The research interest goes beyond sweetness, though. Rare sugars are now studied for their effects on gut hormones and blood sugar control. GLP-1 is one of those hormones. It is released from the gut and helps regulate appetite and insulin. Scientists want to know if rare sugars trigger it directly. This paper gives some of the clearest preclinical evidence yet.

What the study did

Researchers gave mice a single oral dose of D-allulose. They used two doses: 1 g/kg body weight and 3 g/kg body weight. Then they sampled portal plasma, which is blood leaving the gut, and measured active GLP-1. They also tracked food intake.

In a second phase, they gave a GLP-1 receptor antagonist called exendin(9-39). The goal was to see whether blocking GLP-1 signaling stopped the food intake effect. This design is clean. It tests both the hormone response and the causal role of the hormone.

Key findings

The table below summarizes the main results.

Observation	Result	Practical implication
Portal active GLP-1 after 1 g/kg D-allulose	Significant increase	A moderate acute dose triggers GLP-1 release
Portal active GLP-1 after 3 g/kg D-allulose	Significant increase	The effect holds at a higher dose
Short-term food intake	Dose-dependent suppression	More D-allulose led to stronger inhibition
Food intake after exendin(9-39)	Blocked	GLP-1 receptor activation drives the effect

One number stands out: both 1 g/kg and 3 g/kg produced significant rises in active GLP-1. The antagonist completely blocked the feeding suppression. That makes GLP-1 a necessary player here, not just a bystander.

What it means for manufacturers

Don’t overread a mouse study. But do use it to shape product concepts. D-allulose already works as a low-calorie sweetener. If it also triggers GLP-1 release in humans, it could support appetite control claims down the road. That idea fits meal replacements, protein bars, and functional beverages.

Formulators should ask suppliers for dose-response data and gastrointestinal tolerance data. They should also track regulatory status in each target market. This study is preclinical, so it won’t support consumer-facing claims. It can, however, justify early R&D investment and human trial planning.

Ingredient buyers should watch this space. The evidence base for rare sugars is building. D-allulose now has a clear mechanism: GLP-1 release through the gut. That’s a stronger starting point than many other sweeteners.

FAQ

Does this mean D-allulose suppresses appetite in humans?

No. This is a mouse study. Human studies are needed. Use the findings to guide research, not to make claims.

Why did the researchers measure GLP-1 in portal plasma?

Portal plasma comes from the vein heading from the gut to the liver. That’s where intestinal hormones first appear after release. It gives a direct signal of GLP-1 production.

Was the effect seen with long-term feeding?

No. The study measured short-term food intake after a single dose. Long-term effects were not tested.

Consider this a building block. D-allulose has the look of a functional sugar, not just a low-calorie one. The next step is human proof. For now, this paper gives formulators a mechanism worth building around.